- Reimbursement approval from U.S. Centers for Medicare & Medicaid Services (CMS) 29 November 2021
- Exercise of Warrants and Total Voting Rights 29 November 2021
- Manufacturing and Trading Update 04 November 2021
- The Pulse: Healthcare Innovation Breakfast 01 November 2021
- Product wins Top Award at US Trade show 25 October 2021
Second US Distribution Agreement
05 July 2021
LONDON, U.K. AND PLANO, TX, U.S. (5 July 2021). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that, as anticipated, it has signed its second US distribution agreement for its X-PLO2R™ portable oxygen concentrator (“POC”) portfolio. This is the next stage in establishing US-wide distribution coverage as part of the Group’s commercialisation strategy.
The distributor, located in the Midwest US, is a leading nationwide seller of supplemental oxygen and respiratory equipment. The distributor immediately issued its first purchase order with anticipated delivery of the X-PLO2R™ portable oxygen concentrator expected Q3 of this year.
As described in the Company’s Admission Document, Belluscura’s plan is to appoint distributors in the US to give US-wide coverage for the launch of the X-PLO2R™; and this is expected to occur in the second half of 2021 and
About the X-PLO₂R™
The X-PLO₂R™ weighs less than 1.5kg (3.25lbs) and the Directors believe it is the world’s first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other US Food & Drug Administration (“FDA”)
cleared POC in its class. The X-PLO2R™ can deliver up to 95% pure oxygen to patients 24 hours a day, 7 days a week to help improve the quality of life for millions of people worldwide who suffer from chronic lung diseases, such as
Chronic Obstructive Pulmonary Disease and respiratory distress caused by COVID-19. The X-PLO₂R™ is designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices.
In March 2021 Belluscura received 510(k) clearance from the FDA for the X-PLO2R™, which will be launched commercially in Q3 2021. Additional products within the range will be launched within the next 12 months.
Robert Rauker, CEO of Belluscura plc, said: "We continue to be very pleased with the reception the X-PLO2R™ portable oxygen concentrator is receiving from distributors and look forward to commercial launch in Q3 of 2021. We expect to announce additional distribution agreements in the very near future.”
For further information please contact:
|Robert Rauker, Chief Executive Officer||via Walbrook PR|
|Anthony Dyer, Chief Financial Officer|
|SPARK Advisory Partners Limited (NOMAD)||Tel: +44 (0)20 3368 3550|
|Dowgate Capital Limited (Broker)||Tel: +44 (0)20 3903 7715|
|James Serjeant / Nicholas Chambers|
|Walbrook PR Ltd (Media & Investor Relations)||Tel: +44 (0)20 7933 8780 or [email protected]|
|Paul McManus / Sam Allen||Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258|
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes
for the patients, healthcare providers and insurance organisations.
About RNS Reach announcements
RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.